Abstract Several clinical trials have shown that the inhaled b 2 -agonists with long-acting properties, formoterol and salmeterol, may be effective in acute exacerbations of chronic obstructive pulmonary disease (COPD).However, there is a greatdeal of controversyregarding the timing and optimal dose of inhaled b 2 -agonistsin this pathologic condition.In this double-blind, randomised, crossover study, we have compared the bronchodilating effect and the safety of inhaled formoterol administered viaTurbuhaler using either a cumulative dose regimen or the equivalent single dose in 16 patients with acute exacerbations of COPD.On the two consecutive days, the patients received, in a randomised order, each of the following active dose regimens: (A): 9 + 9 + 18 mg of formoterol viaTurbuhaler (36 mg cumulative delivered dose), or (B): 36 + 0 + 0 mg of formoterol via Turbuhaler. The three doses on each treatment day were administered at 30-mm intervals, with measurements being made 5 and 30 min after each dose.Contemporaneously, we also measured oxygen saturation by pulse oximetry (SpO 2 ) and pulse rate. Both the high dose and the cumulative one induced a significant bronchodilation expressed as change in FEV 1 .The difference between the two regimens was significant (P=0.0332) only 60 min after the first inhalation.The trend of FVC and IC was similar to that of FEV 1 . All treatment regimens were well tolerated and no adverse events were reported. Neither the administration of the high dose nor that of the cumulative one modified heart rate in a significant manner. Also they did not influence SpO 2 .This study indicates that a single high dose of formoterol is as effective as the same dose administered in a cumulative manner in patients with acute exacerbation of COPD. r
INTRODUCTION
There is a great deal of controversy regarding the timing and optimal dose of inhaled b 2 -agonists in the treatment of acute exacerbations of chronic obstructive pulmonary disease (COPD). Whereas these agents once were administered at a moderate dose every hour, there has been a trend towards increasing frequency and size of dosing for inhaled b-agonists (1). However, one study failed to demonstrate a signi¢cant advantage by giving salbutamol more frequently than once every 60 min (2) .
Several clinical trials have shown that the inhaled b 2 -agonists along with long-acting properties, formoterol and salmeterol, may be e¡ective in acute exacerbations of COPD when administered as cumulative doses (3^5). Rodriguez-Roisin (6) correctly de¢ned an acute exacerbation of COPD as a sustained worsening of the patient's condition, from the stable state and beyond normal dayto-day variations, that is, acute in onset and necessitating a change in regular medication in a patient with underlying COPD.The sustained worsening of the patient's condition is the best reason to use higher than customary dosage of long-acting b 2 -agonists in the treatment of acute exacerbation of COPD (5) . It is now mandatory to examine if high doses of these long-acting inhaled b 2-agonists are as e¡ective as the same doses administered in a cumulative manner.
In this study, we have compared the bronchodilating e¡ect and the safety of inhaled formoterol administered using either a cumulative dose regimen or the equivalent single dose in patients with acute exacerbations of COPD.
METHODS

Study design
The study was of a double-blind, double-dummy, randomised, crossover design taking place over two consecutive days. All work was conducted according to the rules of the Declaration of Helsinki. An independent review board for human studies approved the protocol. Informed written consent was obtained from the patients.
Patients
Sixteen patients with acute exacerbation of COPD (anthonisen exacerbation type I or II), and who were willing to participate, were recruited (Table 1) . Their ages ranged from 51 to 77 years. Six of them were smokers and 10 ex-smokers. The diagnosis of COPD was consistent with the diagnostic standards of European Respiratory Society (ERS) for the management of COPD (7) . Acute exacerbation was de¢ned as a sustained worsening of the patient's condition, from the stable state and beyond normal day-to-day variations [current FEV 1 (forced expiratory volume in one second) always less than 70% of their best], that is, acute in onset and necessitating a change in regular medication in a patient with underlying COPD (6) . All patients had no indication for hospitalisation, according to the British Thoracic Society (BTS) Guidelines (8) . The number of patients for this study was not calculated because it was a pilot investigation.
A bronchodilator response prior to entry into the study was not required, but all patients were able to perform a forced expiratory manoeuvre. Patients with a history of asthma, allergic rhinitis, atopy, or with a total blood eosinophil count over 400/mm 3 were excluded. Patients were also excluded if they had comorbidities (such as congestive heart failure or pulmonary embolus) or complications of COPD (e.g. pneumothorax) as the aetiology of exacerbation of their symptoms. No patient was su¡ering from febrile tracheobronchitis.
Additional medication
Oral bronchodilators were not permitted during the study. Short-acting inhaled b 2 -agonists were permitted soon after each test when required. All patients received a treatment with an oral antibiotic (co-amoxiclav or levo£oxacin) and an inhaled steroid (budesonide 400 mg or £uticasone 250 mg twice daily),
Patients were asked not to consume cola drinks, co¡ee or tea and not to smoke in the hours before and during the investigation.
Treatment
On the two consecutive days, the patients received, in a randomised order, each of the following active dose regimens: (A): 9 + 9 + 18 mg of formoterol via Turbuhaler (36 mg cumulative delivered dose equivalent to cumulative metered dose of 48 mg). Treatments were double-blinded, using Turbuhaler placebo inhalers; active inhalation was performed ¢rst. Patients always inhaled four consecutive doses. All inhalations were made by administering either formoterol (9 mg/inhalation) or placebo. Eight patients received treatment (A) on the ¢rst day and treatment (B) on the second day, while the other eight received treatment (B) on the ¢rst day and treatment (A) on the second day.
The three doses on each treatment day were administered at 30 -mm intervals, with measurements being made 5 and 30 min after each dose.
Spirometric testing was performed according to the procedures described in the AmericanThoracic Society's (ATS) 1987 update (9) . Two acceptable forced expiratory manoeuvres were performed. The highest FVC (forced vital capacity), IC (inspiratory capacity) and FEV 1 , obtained from one of the curves, were kept for analysis. Contemporaneously, we also measured oxygen saturation by pulse oximetry (SpO 2 ) and pulse rate. Pulse oximetry was performed with the patient breathing room air.
Statistics
The maximum FEV 1 value during the dose^response curve to formoterol or salmeterol was chosen as the primary outcome variable to compare the two treatments. Spirometric data, heart rate and SpO 2 values for each treatment were analysed using the Student's t-test for paired variables. Mean responses were also compared by multifactorial analysis of variance (ANOVA) to establish any signi¢cant overall e¡ect between the two treatments. In the presence of a signi¢cant overall ANOVA, Duncan's multiple range testing with 95% con¢dence limits was used to Identify where di¡erences were significant. A probability level of Po0.05 was considered as signi¢cant for all tests. All data analysis were performed using computer software (GB-STAT, Version 8.0, Dynamic Microsystems, Inc, Silver Spring, MD 20904, U.S.A). In particular, for the cumulative treatment regimen, each new dose produced an increase in FEV 1 suggesting that the dose^response plateau had not been reached. The di¡erence between the two regimens was signi¢cant (P=0.0332) only 60 min after the ¢rst inhalation. The trend of FVC and IC was similar to that of FEV 1 (Fig. 2) .
RESULTS
All
All treatment regimens were well tolerated and no adverse events were reported. Neither the administration of the high dose nor that of the cumulative one modi¢ed heart rate in a signi¢cant manner. Also, they did not in£uence SpO 2 (Table 2) . Di¡erences between the two manners of administration of the same dose of formoterol were not signi¢cant. 
DISCUSSION
This study indicates that a single high dose of formoterol is as e¡ective as the same dose administered in a cumulative manner in patients with acute exacerbation of COPD.
This ¢nding was unexpected considering that it has been suggested that the use of a cumulative technique to obtain bronchodilator dose^response curves will cause a greater response than a non-cumulative technique, because sequential doses of drug will penetrate further into the lung (10, 11) . Practically, Britton and Tatters¢eld observed that the bronchodilator response to isoprenaline was less when administered as single doses of 10, 20, 80, and 400 mg when compared with the same doses given according to a cumulative regimen in patients with asthma (11) . Recently, it has been documented that the e¡ect on FEV 1 of 400 mg inhaled salbutamol administered viaTurbuhaler using a cumulative dose regimen was (also) greater than the equivalent single dose, always in subjects with asthma (12) .
It is di⁄cult to explain the di¡erences between the responses in patients with acute exacerbation of COPD that we have observed in this study, and those in asthmatic subjects documented by other researchers (10^12).
We could hypothesise that the use of di¡erent agents induces di¡erent pharmacodynamic behaviours independently from the treated pathology. In e¡ect, in vitro estimates suggest that the bronchodilating potency of formoterol may be 100^200 times greater than that of salbutamol on a molar basis (13, 14) i.e. about 601 20 times greater on a weight basis. If this ¢nding is true also in humans in vivo, it means that 48 mg of formoterol is a more potent dose than 400 mg of salbutamol and is a dose able to induce a fast and generalised bronchodilation. In other words, this dose, which we could call ''relative saturation dose'', would be great enough to open the majority of those pulmonary areas that are without anatomical damage. On the contrary, 400 mg of salbutamol might not be su⁄cient to elicit the same e¡ect and, for this reason, patients could draw bene¢t from the progressive opening of new pulmonary areas that is subsequent to the inhalation of increasing doses of this bronchodilator. In e¡ect, as correctly described by Fishwick et al. (12) , the ¢rst dose partially opens up the constricted lung, but the dose needed for this ''¢rst maximal bronchodilation'' is far below the doses usually given.The next dose given will reach ''new'' areas of the lung and thus the bronchodilator e¡ect will increase further. This will result in a dose^response curve that gradually approaches a maximum. However, we have documented that there was no signi¢cant di¡erence between FEV 1 , IC and FVC values after 48 mg formoterol and 800 mg salbutamol in patients su¡ering from acute exacerbation of COPD (4) when a dose-response curve has been constructed.
It is also possible that the di¡erence in the treated pathology might be another reason of the di¡erent behaviour between patients with asthma and those su¡ering from acute exacerbation of COPD. It might be hypothesised that the non-cumulative technique causes a greater response than the dose^response curves patients with COPD, contrary to what is observed in asthma because in COPD air£ow is limited mainly by structural alterations within and around peripheral airways (15) . These anatomic changes prevent access of b-agonists to the periphery of the lung where the highest concentration of b-adrenoceptors is found (16) . Consequently, better penetration of aerosol into the airways partially dilated by preceding treatment is unimportant in this case. On the contrary, the non-cumulative technique permits the inhalation of a high amount of drug that reaches b 2 -adrenoceptors which are present also in the larger airways, and activates a larger number of these receptors. Leaving out of consideration the reasons that justify the described behaviour in patients with acute exacerbations of COPD, we must underline that the single highdose regimen also seems to be as safe as the cumulative one. This ¢nding has important clinical implications with respect to the utilization of bronchodilator aerosols in the treatment of acute exacerbation of COPD. In fact, because side e¡ects are minimal, it would be reasonable to use 36 mg of nebulised formoterol as initial therapy of acute exacerbation of COPD. In our opinion, this posologic approach is preferable to prescription of the equivalent cumulative dose regimen when it does not involves additional risks because it simpli¢es the assumption of bronchodilator. Alternatively, if there are potential risks for side e¡ects, dose^response titration with formoterol would be advantageous although some degree of side e¡ects from b-agonist use is tolerable in an acute situation to achieve a critical therapeutic e¡ect (17) .
